Bassem I. Yamout

Beirut, BA, Lebanon

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 128 publications

Causal effects of multiple sclerosis therapies in left-truncated registry data.

Causal effects of multiple sclerosis therapies in left-truncated registry data.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: July 21, 2026

Modified Delphi consensus on the use of cladribine tablets in relapsing-remitting multiple sclerosis in North-West Africa.

Modified Delphi consensus on the use of cladribine tablets in relapsing-remitting multiple sclerosis in North-West Africa.

Journal: Multiple sclerosis and related disorders

Published: April 05, 2026

Managing reactivation of multiple sclerosis during treatment with natalizumab.

Managing reactivation of multiple sclerosis during treatment with natalizumab.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: December 20, 2025

Evaluation of the performance of large language models in responding to medical questions related to multiple sclerosis: A case study of large language models including ChatGPT, Gemini, Grok and Copilot.

Evaluation of the performance of large language models in responding to medical questions related to multiple sclerosis: A case study of large language models including ChatGPT, Gemini, Grok and Copilot.

Journal: PloS one

Published: October 23, 2025

Long-term Real-world Safety and Efficacy of Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis: The UAE Experience.

Long-term Real-world Safety and Efficacy of Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis: The UAE Experience.

Journal: Multiple sclerosis and related disorders

Published: September 01, 2025

Directions for advancing prognostic assessments in multiple sclerosis: Qualitative Insights from MS specialist Interviews.

Directions for advancing prognostic assessments in multiple sclerosis: Qualitative Insights from MS specialist Interviews.

Journal: Journal of the neurological sciences

Published: August 25, 2025

Expert consensus on the clinical use of cladribine tablets for treating relapsing multiple sclerosis in the asia-pacific region.

Expert consensus on the clinical use of cladribine tablets for treating relapsing multiple sclerosis in the asia-pacific region.

Journal: Multiple sclerosis and related disorders

Published: August 17, 2025

Real-world effectiveness of horizontal switching between disease-modifying therapies in multiple sclerosis: a retrospective analysis of the MSBase Registry.

Real-world effectiveness of horizontal switching between disease-modifying therapies in multiple sclerosis: a retrospective analysis of the MSBase Registry.

Journal: Therapeutic advances in neurological disorders

Published: July 02, 2025

The real-world effectiveness and safety of off-label rituximab in a large cohort of Middle Eastern multiple sclerosis patients.

The real-world effectiveness and safety of off-label rituximab in a large cohort of Middle Eastern multiple sclerosis patients.

Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

Published: June 19, 2025

Consensus Recommendations for the Diagnosis and Treatment of Neuromyelitis Optica Spectrum Disorders (NMOSD): The MENACTRIMS Guidelines.

Consensus Recommendations for the Diagnosis and Treatment of Neuromyelitis Optica Spectrum Disorders (NMOSD): The MENACTRIMS Guidelines.

Journal: CNS drugs

Published: April 21, 2025

Moderate-high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosis.

Moderate-high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosis.

Journal: Journal of neurology, neurosurgery, and psychiatry

Published: April 15, 2025

Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis.

Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis.

Journal: JAMA neurology

Published: April 14, 2025

Showing 1-12 of 128

Last Updated: 09/26/2026